Spago Nanomedical AB (SPAGO) NPV

Spago Nanomedical AB (publ), formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. The Company is a nanomedicine company in clinical development phase, developing products for diagnostics and treatment of life-threatening and debilitating diseases. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The Company’s operations are based on a patented material for the design of functional nanoparticles that accumulate physiologically in tumors, thus enabling higher precision in image diagnostics and treatment of cancer and other severe diseases.